The main challenge was incomplete adherence to repeat PSA testing.<h4>Conclusion</h4>The CROState pilot demonstrated high initial participation and high detection rate of prostate cancer, with a few clinically insignificant tumors, when combining PSA testing with advanced imaging and targeted biopsy. This evidence concerns the gene KLK3 and prostate carcinoma.